An Update of Patents, Preclinical and Clinical Outcomes of Lipid Nanoparticulate Systems.

abstract：BACKGROUND:The drug delivery of macromolecules such as proteins and peptides has become an important area of research and represents the fastest expanding share of the market for human medicines. The most common method for delivering macromolecules is parenterally. However parenteral administration of some therapeutic ...

journal_title：Current pharmaceutical design

authors： Shadab M,Haque S,Sheshala R,Meng LW,Meka VS,Ali J

更新日期：2017-01-01 00:00:00

abstract：:Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic relapsing conditions resulting from immune system activity in a genetically predisposed individual. IBD is based on progressive damage to the inflamed gut tissue. As its pathogenesis remains unknown, recent accumu...

journal_title：Current pharmaceutical design

authors： Alimohammadi N,Koosha F,Rafeian-Kopaei M

更新日期：2020-01-01 00:00:00

abstract：:Obesity, a chronic low-grade inflammation disorder characterized by an expansion in adipose tissue mass, is rapidly expanding worldwide leading to an increase in the incidence of comorbidities such as insulin resistance, type 2 diabetes and cardiovascular diseases. This has led to a renewed interest in the adipose tis...

journal_title：Current pharmaceutical design

authors： Landini L,Honka MJ,Ferrannini E,Nuutila P

更新日期：2016-01-01 00:00:00

abstract：:NAP (davunetide) is an eight amino acid peptide (NAPVSIPQ) that has been shown to provide potent neuroprotection, in vitro and in vivo. In human clinical trials, NAP has been shown to increase memory scores in patients suffering from amnestic mild cognitive impairment, a precursor to Alzheimer's disease and to enhance...

journal_title：Current pharmaceutical design

authors： Gozes I

更新日期：2011-01-01 00:00:00

abstract：BACKGROUND:Ximelagatran has been approved in Europe for VTE prophylaxis in orthopedic surgery at fixed doses and without laboratory monitoring. Aim of the study was to evaluate safety and efficacy of ximelagatran in a meta-analysis of prophylaxis and/or treatment randomized controlled trials. METHODS:Absolute risk of ...

journal_title：Current pharmaceutical design

authors： Iorio A,Guercini F,Ferrante F,Nenci GG

更新日期：2005-01-01 00:00:00

abstract：:Nitric oxide is a ubiquitous molecule involved in a variety of biological processes. The specific action of NO depends on its enzymatic sources namely neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and inducible NOS (iNOS) and all three isoforms have been localized in the gastrointestinal tract. Constit...

journal_title：Current pharmaceutical design

authors： Barrachina MD,Panés J,Esplugues JV

更新日期：2001-01-01 00:00:00

abstract：:Many of the most debilitating symptoms for psychiatric disorders such as schizophrenia remain poorly treated. As such, the development of novel treatments is urgently needed. Unfortunately, the costs associated with high failure rates for investigational compounds as they enter clinical trials has led to pharmaceutica...

journal_title：Current pharmaceutical design

authors： Wylie KP,Smucny J,Legget KT,Tregellas JR

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:Discovery and development of BCS class 1 drugs through high throughput screening is one of the biggest challenge faced by formulation scientist. METHODS:There are a number of approaches that have been exploited to enhance the solubility and permeability of drugs. Among them, development of nanosuspension ha...

journal_title：Current pharmaceutical design

authors： Arora D,Khurana B,Rath G,Nanda S,Goyal AK

更新日期：2018-01-01 00:00:00

abstract：:Combinations of different technologies are at the heart of the development and implementation of new, innovative processes and approaches for Industry 4.0 in the field of medicinal chemistry and drug discovery. Process intensification and advances in high-throughput synthetic techniques can dramatically improve reacti...

journal_title：Current pharmaceutical design

authors： Tagliapietra S,Binello A,Bucciol F,Trukhan V,Colia M,Cravotto G

更新日期：2020-01-01 00:00:00

abstract：:Mitochondria are involved in different physiological and pathological processes that are crucial for tumor cell physiology, growth and survival. Since cancer cells have frequently disrupted different cell death pathways that promote their survival, mitochondria may be key organelles to promote cell death in cancer cel...

journal_title：Current pharmaceutical design

authors： Ferrín G,Linares CI,Muntané J

更新日期：2011-01-01 00:00:00

abstract：:During the last years, mass spectrometry has revolutionised protein biochemistry and has advanced to a superior tool for the identification and detailed analysis of peptides and proteins. The high throughput allowed by some mass spectrometry platforms has enabled the important step from analysis of individual proteins...

journal_title：Current pharmaceutical design

authors： Pusch W,Kostrzewa M

更新日期：2005-01-01 00:00:00

abstract：:Adenosine is released in large amounts during myocardial ischemia and is capable of exerting potent cardioprotective effects in the heart. Although these observations on adenosine have been known for a long time, how adenosine acts to achieve its anti-ischemic effect remains incompletely understood. However, recent ad...

journal_title：Current pharmaceutical design

authors： Liang BT,Jacobson KA

更新日期：1999-12-01 00:00:00

abstract：:Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medicat...

journal_title：Current pharmaceutical design

authors： Iacobellis G,Sharma AM

更新日期：2007-01-01 00:00:00

abstract：:We illustrate the use of quantitative proteomics, namely isotope-coded affinity tag labelling and tandem mass spectrometry, to assess the targets and effects of the blockade of matrix metalloproteinases by an inhibitor drug in a breast cancer cell culture system. Treatment of MT1-MMP-transfected MDA-MB-231 cells with ...

journal_title：Current pharmaceutical design

authors： Butler GS,Overall CM

更新日期：2007-01-01 00:00:00

abstract：:Sarcopenia is defined as the loss of muscle mass associated with a loss of muscle function, e.g., walking speed. A number of consensus definitions exist for sarcopenia with cut-off points being ethnically specific. A rapid screen test (SARC-F) is available and does not require different ethnic cut-off points. Sarcopen...

journal_title：Current pharmaceutical design

authors： Morley JE

更新日期：2017-11-28 00:00:00

abstract：:DNA-topoisomerases, a family of DNA-processing enzymes, represent the pharmacological target of major clinically useful chemotherapeutic agents. These drugs essentially act by trapping a topoisomerase-DNA cleavable complex, an intermediate in the enzyme s catalytic cycle. Research activity in this field continues to g...

journal_title：Current pharmaceutical design

authors： Gatto B,Capranico G,Palumbo M

更新日期：1999-03-01 00:00:00

abstract：:The prevalence of fungal infections of skin has increased rapidly, affecting approximately 40 million people across the globe. A wide variety of antifungal drugs has been utilized in the effective management of numerous dermatological infections. Topical treatment of fungal infections has proved to be quite advantageo...

journal_title：Current pharmaceutical design

authors： Akhtar N,Verma A,Pathak K

更新日期：2015-01-01 00:00:00

abstract：:The antifungal agents for systemic mycoses are only a few in number. Among them amphotericin-B is still the most widely used drug, but substantial side effects including nephrotoxicity limits its clinical usefulness. Efforts to lower the toxicity are synthesis of AMPH-B analogues such as AMPH-B esters and encapsulatio...

journal_title：Current pharmaceutical design

authors： Maesaki S

更新日期：2002-01-01 00:00:00

abstract：:The Hereditary Spastic Paraparesis (HSP) or Strumpell-Lorrain disease is a heterogeneous neurodegenerative disease of the spinal cord. It is genetically transmitted and characterized by a progressive muscle weakness, spasticity of the lower limbs and awkward gain. There is no specific pharmacological treatment. The ph...

journal_title：Current pharmaceutical design

authors： Riccardo M,Angela L,Angela D,Vita P,Giulio L,Pietroq F,Giancarlo I,Marisa M

更新日期：2016-01-01 00:00:00

abstract：:Agomelatine markedly differs from other classes of antidepressant drugs: its primary molecular targets in vivo are the melatonin MT(1) and MT(2) receptors, where it acts as a potent agonist, and the 5-HT(2C) receptors, where it exerts clear-cut antagonist properties. Agomelatine across a wide range of clinical trials ...

journal_title：Current pharmaceutical design

authors： Bourin M,Prica C

更新日期：2009-01-01 00:00:00

abstract：:Active pharmaceutical ingredients (APIs) can exist in different polymorphic forms as well as in amorphous state. Polymorphic and amorphous forms of APIs can differ in physicochemical properties which in turn can significantly influence their therapeutic safety and effectiveness of the treatment. This review focuses on...

journal_title：Current pharmaceutical design

authors： Talaczynska A,Dzitko J,Cielecka-Piontek J

更新日期：2016-01-01 00:00:00

abstract：:Polyunsaturated fatty acids (PUFA) are a family of lipids including some subgroups identified by the position of the last double bond in their structure. PUFA n-3 include alpha linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), while PUFA n-6 include linoleic acid (LA) and arachidonic a...

journal_title：Current pharmaceutical design

authors： Zuliani G,Galvani M,Leitersdorf E,Volpato S,Cavalieri M,Fellin R

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Glioma is the most common human central nervous system tumour with a high degree of malignancy. Some Rab GTPases have significant effects on glioma. OBJECTIVE:This study aimed to investigate the effect of Rab3b (Rab GTPase3b) on human glioma cell proliferation and apoptosis by silencing Rab3b and to initial...

journal_title：Current pharmaceutical design

authors： Luo Q,Liu Y,Yuan Z,Huang L,Diao B

更新日期：2020-09-17 00:00:00

abstract：:Synaptic plasticity is now known to occur at glutamate synapses throughout the brain, including the neocortex, and to play a role in neurodevelopment as well as in a broad spectrum of adult neural functions. Here the hypothesis that synaptic plasticity, specifically long term depression, is the neural substrate that m...

journal_title：Current pharmaceutical design

authors： Selemon LD

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a novel category of oral antidiabetic drugs that inhibit renal glucose reabsorption and increase renal glucose excretion, thus lowering plasma glucose levels. This unique mechanism of SGLT2i action is insulin independent, thus improving glycemic control ...

journal_title：Current pharmaceutical design

authors： Katsiki N,Mikhailidis DP,Theodorakis MJ

更新日期：2017-01-01 00:00:00

abstract：BACKGROUND:According to the World Health Organization (WHO), diabetes mellitus is considered the 7th leading cause of death as of 2016, while almost half of all deaths related to high blood glucose occur before the age of 70. According to the 2019 American Diabetes Association's (ADA) guidelines, metformin is the first...

journal_title：Current pharmaceutical design

authors： Gillani SW,Moosvi AF

更新日期：2020-01-01 00:00:00

abstract：:Neglected parasitic diseases are a group of infections currently considered as a worldwide concern. This fact can be attributed to the migration of these diseases to developed and developing countries, associated with therapeutic insufficiency resulted from the low investment in the research and development of new dru...

journal_title：Current pharmaceutical design

authors： Albino SL,da Silva JM,de C Nobre MS,de M E Silva YMS,Santos MB,de Araújo RSA,do C A de Lima M,Schmitt M,de Moura RO

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND AND OBJECTIVES:The 3' repair exonuclease 1 (TREX1) gene is the major DNA-specific 3'-5 'exonuclease of mammalian cells which reduces single- and double-stranded DNA (ssDNA and dsDNA) to prevent undue immune activation mediated by the nucleic acid. TREX1 is also a crucial suppressor of selfrecognition that pr...

journal_title：Current pharmaceutical design

authors： Tao SS,Wu GC,Zhang Q,Zhang TP,Leng RX,Pan HF,Ye DQ

更新日期：2019-01-01 00:00:00

abstract：:Locomotion is one of the most complex motor behaviors. Locomotor patterns change during early life, reflecting development of numerous peripheral and hierarchically organized central structures. Among them, the spinal cord is of particular interest since it houses the central pattern generator (CPG) for locomotion. Th...

journal_title：Current pharmaceutical design

authors： Brumley MR,Guertin PA,Taccola G

更新日期：2017-01-01 00:00:00

abstract：:Both high arterial blood pressure (BP) and elevated levels of fine particulate matter (PM2.5) air pollution have been associated with an increased risk for several cardiovascular (CV) diseases, including stroke, heart failure, and myocardial infarction. Given that PM2.5 and high BP are each independently leading risk ...

journal_title：Current pharmaceutical design

authors： Giorgini P,Di Giosia P,Grassi D,Rubenfire M,Brook RD,Ferri C

更新日期：2016-01-01 00:00:00